AIM ImmunoTech (AIM) Enterprise Value (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Enterprise Value came in at -$5.9 million in Q1 2026, down 161.64% YoY from $9.5 million in Q1 2025, and down 92.94% on a QoQ basis from -$3.0 million in Q4 2025.
AIM ImmunoTech (AIM) Enterprise Value (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Enterprise Value data on file, last reported at -$5.9 million in Q1 2026.
- Quarterly Enterprise Value fell 161.64% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.9 million (down 161.64% YoY) and the FY2025 annual result came in at -$3.0 million, up 69.36% from the prior year.
- Enterprise Value eased to -$5.9 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$835000.0 in Q2 2025 to a low of -$41.8 million in Q2 2022.
- A 5-year average of -$17.0 million and a median of -$10.9 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value surged 91.7% — and 2026, when it slumped 161.64%.
- Tracing AIM's Enterprise Value over 5 years: stood at -$34.2 million in 2022, then soared by 61.77% to -$13.1 million in 2023, then rose by 23.91% to -$9.9 million in 2024, then soared by 69.36% to -$3.0 million in 2025, then tumbled by 92.94% to -$5.9 million in 2026.
- The last three Enterprise Value figures came in at -$5.9 million (Q1 2026), -$3.0 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | -9.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.96 Mn |
| Mar 31, 2026 | -5.88 Mn |
| Dec 31, 2025 | -3.05 Mn |
| Sep 30, 2025 | -2.41 Mn |
| Jun 30, 2025 | -835,000.00 |
| Mar 31, 2025 | -2.25 Mn |
| Dec 31, 2024 | -9.95 Mn |
| Sep 30, 2024 | -7.20 Mn |
| Jun 30, 2024 | -10.06 Mn |
| Mar 31, 2024 | -10.94 Mn |
| Dec 31, 2023 | -13.07 Mn |
| Sep 30, 2023 | -22.43 Mn |
| Jun 30, 2023 | -28.40 Mn |
| Mar 31, 2023 | -30.85 Mn |
| Dec 31, 2022 | -34.19 Mn |
| Sep 30, 2022 | -36.75 Mn |
| Jun 30, 2022 | -41.77 Mn |
| Mar 31, 2022 | -28.99 Mn |
| Dec 31, 2021 | -48.27 Mn |
| Sep 30, 2021 | -53.86 Mn |